The more complicated a primary endpoint, the greater a puzzle it can be for clinicians to interpret the results. It's likely even tougher for patients, who don't help choose the events studied in clinical trials yet are increasingly sharing in the management decisions they influence Continue reading →

Previously reported benefits of alcohol intake for patients with cardiovascular disease appear to be partially mediated through modulation of stress-associated brain activity, a new study suggests. Continue reading →

SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at the American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21) taking place online from May 15, 2021 - May 17, 2021. Included among these presentations will be a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship to patient baseline ejection fraction, in a Late Breaking Clinical Trial session. Late Breaking Clinical Trial Session Title: 410-16 Impact of Ejection Fraction on the Therapeutic Effect of Omecamtiv Mecarbil In Patients with Heart Failure and Reduced Ejection Fraction: A Secondary Analysis From GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) Presenter: John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF Date: May 17, 2021 Session Title: Late-Breaking Clinical Trials IV Session Time: 8:00 9:15 AM ET Presentation Time: 9:00 9:10 AM ET Poster Presentations The following posters will be available on demand for registered attendees beginning on May 15, 2021 at 8:00 AM ET. Continue reading →

NEW YORK--(BUSINESS WIRE)--Heartbeat Health, a healthcare company working to deliver the most effective, efficient, and engaging heart care, announced today that it has raised $20 million in Series B funding, led by Echo Health Ventures, with participation from DaVita Venture Group and existing investors, .406 Ventures, Optum Ventures, Kindred Ventures, Lerer Hippeau, Designer Fund and Max Ventures. Heartbeat Health was founded with a mission to fundamentally reshape cardiovascular care to better address heart disease, the costliest and deadliest disease globally. Heartbeat delivers virtual-first cardiovascular disease prevention and management with a focus on improved clinical experience, health outcomes, and reduced costs Continue reading →

Written by Julia Ries on May 7, 2021 Fact checked by Dana K. Continue reading →

Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast. For the week ending May 7, 2021, John Mandrola, MD comments on the following news and features stories. Continue reading →

Treatment with canagliflozin may not provide a significant reduction in myocardial infarction (MI) risk among patients with type 2 diabetes (T2D) and comorbid chronic kidney disease (CKD) or among patients with diabetes who have a history of or have a high risk for cardiovascular disease (CVD), a study in Cardiovascular Research suggested. The study was a pooled analysis of 14,543 patients from the CANVAS program and CREDENCE trial Continue reading →